NASDAQ:MCRB - Seres Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$8.88 +0.14 (+1.60 %)
(As of 06/19/2018 04:00 PM ET)
Previous Close$8.74
Today's Range$8.65 - $8.94
52-Week Range$6.65 - $17.42
Volume159,200 shs
Average Volume150,322 shs
Market Capitalization$345.55 million
P/E Ratio-4.02
Dividend YieldN/A
Seres Therapeutics logoSeres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. Its lead product candidate is SER-109, a bacterial spore ecology, which is in Phase III clinical study to treat multiply recurrent Clostridium difficile infection (CDI). The company is also developing SER-287 that is in Phase Ib clinical study in patients with mild-to-moderate ulcerative colitis; and SER-262, a multi-strain Ecobiotic microbiome therapeutic candidate, which is in Phase Ib study in patients with primary CDI. In addition, its product candidates in pre-clinical development comprise SER-301, an Ecobiotic microbiome therapeutic candidate for the treatment of inflammatory bowel disease; SER-401 for use with checkpoint inhibitors in patients with solid tumors; and SER-155, an Ecobiotic microbiome therapeutic candidate for the prevention of transplant-related mortality. Seres Therapeutics, Inc. has a strategic collaboration with Nestle Health Science and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Receive MCRB News and Ratings via Email

Sign-up to receive the latest news and ratings for MCRB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations


Debt-to-Equity Ratio0.85
Current Ratio3.60
Quick Ratio3.60


Trailing P/E Ratio-4.02
Forward P/E Ratio-3.51
P/E GrowthN/A

Sales & Book Value

Annual Sales$32.10 million
Price / Sales11.25
Cash FlowN/A
Price / CashN/A
Book Value$1.50 per share
Price / Book5.92


EPS (Most Recent Fiscal Year)($2.21)
Net Income$-89,380,000.00
Net Margins-277.79%
Return on Equity-150.44%
Return on Assets-47.26%


Outstanding Shares40,650,000

Seres Therapeutics (NASDAQ:MCRB) Frequently Asked Questions

What is Seres Therapeutics' stock symbol?

Seres Therapeutics trades on the NASDAQ under the ticker symbol "MCRB."

How were Seres Therapeutics' earnings last quarter?

Seres Therapeutics Inc (NASDAQ:MCRB) announced its quarterly earnings results on Wednesday, May, 9th. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.75) by $0.06. The biotechnology company had revenue of $3.97 million for the quarter, compared to the consensus estimate of $3 million. Seres Therapeutics had a negative net margin of 277.79% and a negative return on equity of 150.44%. View Seres Therapeutics' Earnings History.

When is Seres Therapeutics' next earnings date?

Seres Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for Seres Therapeutics.

What price target have analysts set for MCRB?

8 brokers have issued 12-month price targets for Seres Therapeutics' stock. Their forecasts range from $19.00 to $20.00. On average, they anticipate Seres Therapeutics' share price to reach $19.3333 in the next twelve months. View Analyst Ratings for Seres Therapeutics.

Who are some of Seres Therapeutics' key competitors?

Who are Seres Therapeutics' key executives?

Seres Therapeutics' management team includes the folowing people:
  • Dr. Roger James Pomerantz, Chairman, Pres & CEO (Age 61)
  • Dr. Noubar B. Afeyan Ph.D., Co-Founder & Lead Independent Director (Age 55)
  • Mr. Thomas J. DesRosier, Chief Legal Officer, Exec. VP & Sec. (Age 63)
  • Mr. Eric D. Shaff, COO, CFO, Exec. VP & Principal Accounting Officer (Age 42)
  • Dr. John G. Aunins, CTO and Exec. VP of Bioprocess & Manufacturing (Age 57)

When did Seres Therapeutics IPO?

(MCRB) raised $101 million in an initial public offering on Friday, June 26th 2015. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Leerink Partners and Canaccord Genuity were co-managers.

Has Seres Therapeutics been receiving favorable news coverage?

News articles about MCRB stock have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Seres Therapeutics earned a media sentiment score of 0.10 on Accern's scale. They also gave news stories about the biotechnology company an impact score of 44.92 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

Who are Seres Therapeutics' major shareholders?

Seres Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include NESTLE HEALTH SCIENCE US HOLDINGS, INC. (16.97%), BlackRock Inc. (4.48%), Federated Investors Inc. PA (4.35%), JPMorgan Chase & Co. (1.04%), Millennium Management LLC (0.21%) and Spark Investment Management LLC (0.20%). Company insiders that own Seres Therapeutics stock include David N Cook, Eric D Shaff, John G Aunins, Michele Trucksis and Roger Pomerantz. View Institutional Ownership Trends for Seres Therapeutics.

Which institutional investors are selling Seres Therapeutics stock?

MCRB stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, JPMorgan Chase & Co. and BlackRock Inc.. Company insiders that have sold Seres Therapeutics company stock in the last year include David N Cook, John G Aunins and Roger Pomerantz. View Insider Buying and Selling for Seres Therapeutics.

Which institutional investors are buying Seres Therapeutics stock?

MCRB stock was bought by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA, Spark Investment Management LLC, A.R.T. Advisors LLC and Alps Advisors Inc.. View Insider Buying and Selling for Seres Therapeutics.

How do I buy shares of Seres Therapeutics?

Shares of MCRB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Seres Therapeutics' stock price today?

One share of MCRB stock can currently be purchased for approximately $8.88.

How big of a company is Seres Therapeutics?

Seres Therapeutics has a market capitalization of $345.55 million and generates $32.10 million in revenue each year. The biotechnology company earns $-89,380,000.00 in net income (profit) each year or ($2.21) on an earnings per share basis. Seres Therapeutics employs 138 workers across the globe.

How can I contact Seres Therapeutics?

Seres Therapeutics' mailing address is 200 SIDNEY STREET 4TH FLOOR, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-945-9626.

MarketBeat Community Rating for Seres Therapeutics (MCRB)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  214 (Vote Outperform)
Underperform Votes:  167 (Vote Underperform)
Total Votes:  381
MarketBeat's community ratings are surveys of what our community members think about Seres Therapeutics and other stocks. Vote "Outperform" if you believe MCRB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MCRB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/19/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.